John Theurer Cancer Center at Hackensack University Medical Center 

Hackensack Meridian Health

Hackensack, NJ

Sorting 4 by

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1
  • Myeloma Service

Accepting patients

MMSET Inhibitor

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Learn more
  • Phase 1
  • Myeloma Service
  • 23-222

Accepting patients

CaMMouflage

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Myeloma Service
  • 23-182

Accepting patients

GPC-100

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Learn more
  • Randomization
  • Phase 2
  • Myeloma Service